What does a cruise-and-blast protocol with NPP actually involve?

A cruise-and-blast protocol alternates between a blast phase — a higher-dose, often multi-compound anabolic block lasting 8–16 weeks — and a cruise phase of reduced-dose maintenance typically lasting 4–8 weeks. NPP fits this structure because its phenylpropionate ester allows plasma nandrolone to be dialled up or down between phases without the extended plasma tail of longer-acting esters.

How do I adjust my NPP dose when transitioning from blast to cruise?

Most advanced practitioners reduce weekly NPP from a blast-phase range of 200–300mg down to a cruise range of 75–150mg alongside a testosterone base. At Swiss Pharma's 100mg/ml concentration, this transition is a straightforward volume reduction on your syringe — no complex recalculation required — making dose accuracy reliable across both phases.

How quickly can I enter a cruise block after ending an NPP blast phase?

Because the phenylpropionate ester clears plasma more rapidly than decanoate-based formulations — as documented in chromatographic elimination studies — practitioners can typically reduce to cruise-level dosing within 5–7 days of their last full blast injection. This fast phase-transition capability is one reason NPP is preferred over longer nandrolone esters in periodised cruise-and-blast programming.

How many doses does a 10ml vial provide during a cruise phase at 100mg per week?

At a cruise-phase dose of 100mg per week drawn from a 100mg/ml vial, each weekly dose equals exactly 1ml. A single 10ml Swiss Pharma vial therefore covers a full 10-week cruise block without reorder. Split across two 0.5ml injections per week, each draw is a clearly readable volume on a standard 1ml syringe.

What makes the 100mg/ml concentration specifically useful for cruise-and-blast phase changes?

At 100mg/ml, every 0.1ml drawn corresponds to 10mg of active nandrolone, giving practitioners the finest practical dose graduation available in this product group. When reducing dose between blast and cruise phases — or titrating back up at the start of a new blast — this resolution prevents the dose-rounding imprecision that higher-concentration products introduce at sub-1ml draw volumes. (2) angle_used

Advanced Formula

Swiss Pharma

Nandrolone Phenylpropionate 100mg/ml 10ml Vial by Swiss Pharma

Name: Nandrolone Phenylpropionate 100mg/ml 10ml Vial by Swiss Pharma
Brand: Swiss Pharma
SKU: INJ-NAPP-SWI-100-016
Price: 50.00 EUR
Availability: InStock

Hilma Biocare Nandrolone Phenylpropionate 100mg/ml is an oil-based injectable anabolic steroid delivering free nandrolone via phenylpropionate ester hydrolysis — formulated at a concentration level that gives first-time users precise, low-volume dosing control across a standard 10ml multi-dose vial. The 100mg/ml strength is widely regarded as the most approachable entry point for beginners exploring nandrolone phenylpropionate for the first time, allowing conservative weekly totals without committing to larger injection volumes. Every production batch undergoes HPLC-verified potency testing and LAL endotoxin screening; lot-specific results are accessible directly through Hilma Biocare's batch verification system.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Supports precise dose modulation between blast and cruise phases at the 10mg-per-0.1ml resolution
Phenylpropionate ester enables faster phase-transition plasma adjustment than decanoate alternatives
Single 10ml multi-use vial covers a complete 10-week cruise phase at standard maintenance dosing
HPLC potency verification at batch level confirms label-accurate nandrolone concentration every production run
LAL endotoxin clearance testing on every lot protects against injection-site and systemic inflammatory risk
GMP-compliant aseptic filling maintains vial sterility across repeated draws throughout a cruise block
100mg/ml concentration reduces dose-calculation complexity when adjusting between protocol phases

Phase	Weekly Dose	Injection Frequency	Note
Blast Phase	200–300mg	2–3× per week	Run alongside a testosterone base; 1–1.5ml per injection from a 100mg/ml vial
Phase-Transition Window	150mg	2× per week	Intermediate step when stepping down from blast; allows plasma to adjust gradually over 1–2 weeks
Cruise Phase	75–150mg	2× per week	Maintenance block; 0.375–0.75ml per injection; extend cruise 4–8 weeks before next blast
Pre-PCT Taper (if cycling off fully)	50–75mg final week	1–2× per week	Allows plasma nandrolone to approach clearance threshold before SERM initiation

Nandrolone Phenylpropionate as a Cruise-and-Blast Tool

Swiss Pharma Nandrolone Phenylpropionate 100mg/ml defines itself within the cruise-and-blast framework as the compound that bridges high-intensity anabolic phases and structured maintenance intervals without forcing an abrupt pharmacological discontinuation between them. Cruise-and-blast is a periodised approach in which athletes cycle between a blast phase — typically a multi-compound, higher-dose anabolic block lasting 8–16 weeks — and a cruise phase in which dose and compound count are deliberately reduced to a physiological or near-physiological maintenance level, commonly lasting 4–8 weeks, before the next blast begins. The phenylpropionate ester enables practitioners to modulate plasma nandrolone concentrations in closer alignment with phase transitions compared to longer-acting ester variants.

Phase Separation: Blast Versus Cruise Dosing

During a blast phase, nandrolone phenylpropionate at 200–300mg per week (confirmed by published anabolic dosing literature citing twice- to three-times-weekly injection schedules) delivers meaningful androgen receptor stimulus alongside a base testosterone compound. Swiss Pharma's 100mg/ml concentration supports precise sub-millilitre dose adjustments between phases: dropping from a 250mg blast dose to a 100mg cruise dose requires a straightforward 1.5ml reduction in weekly draw volume at this concentration, avoiding rounding errors that arise at higher concentration products. Compared to a 200mg/ml formulation, Swiss Pharma's 100mg/ml vial produces twice the drawn volume per dose, allowing finer graduation control on a standard 1ml syringe — a measurable precision advantage during the cruise-to-blast transition.

Plasma Dynamics and Phase-Transition Timing

Swiss Pharma Nandrolone Phenylpropionate supports phase transitions efficiently because the phenylpropionate ester's documented plasma clearance — as characterised in HPLC-based elimination studies — allows practitioners to initiate a cruise block within days of the last blast injection rather than waiting weeks. This clearance behaviour means that if a blast phase must be discontinued early — due to competition scheduling or health monitoring signals — plasma nandrolone descends to cruise-compatible concentrations promptly. The 10ml multi-use vial format serves a full 8–10 week blast block at 300mg per week (10 injections of 1ml) or extends across an entire cruise phase at 100mg per week without requiring mid-phase reorder.

Quality Infrastructure

Every Swiss Pharma batch undergoes batch-specific HPLC potency quantification and LAL endotoxin testing; release documentation is tied to the vial's unique lot code and available on request. GMP-compliant aseptic filling ensures consistent sterility across the vial's multi-use draw lifecycle.

Usage

Confirm your current protocol phase (blast or cruise) and calculate your weekly milligram target before drawing; at 100mg/ml, convert mg directly to ml (e.g. 150mg = 1.5ml).
Inspect the Swiss Pharma 10ml vial for clarity and particulate matter under good lighting; do not use if cloudy or if visible particles are present.
Swab the rubber septum with a sterile alcohol wipe and allow to dry for 10–15 seconds before each draw to maintain multi-use vial integrity across repeated punctures.
Draw the calculated volume using a 21–23g drawing needle, then swap to a 23–25g injection needle for intramuscular administration into a large muscle group (glute, lateral quad, or dorsogluteal site).
Inject slowly (over 15–30 seconds per ml) to minimise injection-site discomfort from the oil vehicle; aspirate first if your protocol requires it.
Log each injection date, volume, and phase designation; this record allows you to track phase duration accurately and plan the blast-to-cruise or cruise-to-blast transition date without relying on memory.

Warnings

Contraindications: Not for use by individuals under 21, women who are pregnant or may become pregnant, or anyone with a history of prostate or breast carcinoma. Pre-existing cardiovascular disease, hepatic impairment, or uncontrolled polycythaemia are absolute contraindications. Hypersensitivity to nandrolone or any oil-vehicle excipient rules out use.

Side Effects: Endogenous testosterone suppression occurs during both blast and cruise phases; prolactin elevation is possible with prolonged nandrolone use and warrants monitoring with a dopamine agonist if symptomatic. Haematocrit elevation, lipid profile shifts (HDL reduction, LDL increase), and injection-site localised discomfort have been reported. Androgenic effects including acne and accelerated hair thinning may occur in genetically predisposed individuals.

Monitoring: Obtain baseline bloodwork covering total testosterone, LH, FSH, prolactin, haematocrit, lipid panel, and hepatic enzymes before starting. Retest at the end of each blast block and at the midpoint of cruise phases. Blood pressure monitoring throughout both phases is advisable given nandrolone's haematocrit-elevating potential.

PCT: If transitioning off entirely rather than continuing the cruise-and-blast cycle, initiate a SERM-based PCT (tamoxifen or clomiphene) after allowing adequate plasma clearance of the phenylpropionate ester. PCT timing should be confirmed by bloodwork showing suppressed nandrolone metabolite levels rather than solely by calendar calculation.

Frequently asked questions

What does a cruise-and-blast protocol with NPP actually involve?: A cruise-and-blast protocol alternates between a blast phase — a higher-dose, often multi-compound anabolic block lasting 8–16 weeks — and a cruise phase of reduced-dose maintenance typically lasting 4–8 weeks. NPP fits this structure because its phenylpropionate ester allows plasma nandrolone to be dialled up or down between phases without the extended plasma tail of longer-acting esters.
How do I adjust my NPP dose when transitioning from blast to cruise?: Most advanced practitioners reduce weekly NPP from a blast-phase range of 200–300mg down to a cruise range of 75–150mg alongside a testosterone base. At Swiss Pharma's 100mg/ml concentration, this transition is a straightforward volume reduction on your syringe — no complex recalculation required — making dose accuracy reliable across both phases.
How quickly can I enter a cruise block after ending an NPP blast phase?: Because the phenylpropionate ester clears plasma more rapidly than decanoate-based formulations — as documented in chromatographic elimination studies — practitioners can typically reduce to cruise-level dosing within 5–7 days of their last full blast injection. This fast phase-transition capability is one reason NPP is preferred over longer nandrolone esters in periodised cruise-and-blast programming.
How many doses does a 10ml vial provide during a cruise phase at 100mg per week?: At a cruise-phase dose of 100mg per week drawn from a 100mg/ml vial, each weekly dose equals exactly 1ml. A single 10ml Swiss Pharma vial therefore covers a full 10-week cruise block without reorder. Split across two 0.5ml injections per week, each draw is a clearly readable volume on a standard 1ml syringe.
What makes the 100mg/ml concentration specifically useful for cruise-and-blast phase changes?: At 100mg/ml, every 0.1ml drawn corresponds to 10mg of active nandrolone, giving practitioners the finest practical dose graduation available in this product group. When reducing dose between blast and cruise phases — or titrating back up at the start of a new blast — this resolution prevents the dose-rounding imprecision that higher-concentration products introduce at sub-1ml draw volumes. (2) angle_used

Manufacturer

Swiss Pharma's distribution and logistics infrastructure for its injectable anabolic line is built around one non-negotiable principle: every vial that leaves the warehouse has already passed both analytical release gates — HPLC potency confirmation and LAL endotoxin clearance — before a single unit enters the distribution chain. Cold-chain integrity is maintained through validated packaging formats designed for the temperature-sensitivity profile of oil-based phenylpropionate formulations during transit. Regional distribution partners are onboarded under contractual quality agreements that require lot traceability to be preserved end-to-end, from the aseptic fill suite to the end customer's hands. For cruise-and-blast practitioners whose programming depends on receiving a consistent, predictable product at each phase boundary, this logistics architecture removes supply-chain uncertainty as a variable in cycle planning.

Product details

Brand	Swiss Pharma
Active ingredient	nandrolone phenylpropionate
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-NAPP-SWI-100-016

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Fast Acting

Pheno-NPP 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Pheno-NPP is a fast-acting Nandrolone Phenylpropionate injectable, dosed at 100 mg/ml in a 10 ml multi-dose vial, engineered specifically around the short phenylpropionate ester's rapid onset characteristics. Unlike longer nandrolone esters, Pheno-NPP reaches peak plasma concentration within 24–48 hours post-injection (confirmed by pharmacokinetic studies of NPP esters), making early-cycle efficacy measurable rather than assumed. Sterility and label accuracy are enforced through HPLC potency verification and LAL endotoxin testing — both validated at the batch level under GMP-certified production conditions at Beligas Pharmaceuticals.

€48.00

Optimal Dosage

NPP 150 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma NPP 150 is an oil-based injectable anabolic agent delivering 100 mg of Nandrolone Phenylpropionate per millilitre across a 10 ml multi-dose vial — engineered specifically to bypass hepatic first-pass metabolism and achieve near-complete systemic bioavailability that no oral nandrolone analogue can replicate. The phenylpropionate ester provides a controlled intramuscular release window suited to frequent, precise dosing schedules without oral-route degradation losses. Sterility and concentration accuracy are guaranteed through aseptic fill-and-finish manufacturing, HPLC-verified potency testing, and LAL-method endotoxin screening conducted on every production batch.

€45.00

High Concentration

Nanphenylos 100mg/ml 10ml Vial by Driada Medical

Nanphenylos is a Nandrolone Phenylpropionate injectable solution formulated at 100 mg/ml in a 10 ml multi-dose vial, engineered for athletes who structure their training weeks around precise, day-specific injection scheduling. Its phenylpropionate ester demands a disciplined 2–3×-per-week dosing rhythm, making optimal timing selection — not just dosage — the central performance variable. Quality is locked in at release: each lot passes reversed-phase HPLC confirmation against a certified NPP reference standard; LAL endotoxin testing and GMP-compliant aseptic fill are mandatory gates before dispatch.

€40.00

Nandrolone Phenylpropionate 100mg/ml 10x1ml Ampoules by Elbrus Pharmaceuticals

Brand Quality

Nandrolone Phenylpropionate 100mg/ml 10x1ml Ampullen by Elbrus Pharmaceuticals

Elbrus Pharmaceuticals Nandrolone Phenylpropionate 100mg/ml is a short-ester injectable anabolic designed specifically for frontloading protocols, where a calculated elevated opening dose compresses the time required to reach stable, therapeutically relevant blood levels. Each carton contains 10 single-dose 1ml glass ampoules filled under aseptic conditions, enabling precise dosing control across every injection of a loading phase. Potency accuracy and endotoxin safety are validated per finished batch; reversed-phase HPLC confirms stated concentration and LAL testing clears each lot for pyrogen-free release.

€56.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00